The U.S. Food and Drug Administration approved FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE